Human Cell-based Drug Discovery: Assay Design and Implementation on Relevant Human Cell Platforms

DiscoveryBioMed prefers targeted and phenotypic HTS bioassays (single endpoint or multiplexed endpoints) that feature a relevant human cell line or primary culture as the key ingredient or platform. We consult with each client and/or partner to tailor screening assays to fit individual needs and requirements. DBM's molecular libraries are both targeted and diverse, coming from both synthetic and natural-product (plants, microorganisms) sources. DBM is able to provide screening services that are of high quality, have timely turnaround, have flexible arrangements, and are cost effective.

Custom Cell Engineering: Primary Culture Establishment and Engineered Cell Lines

DBM established its cell culture and engineering infrastructure before its drug discovery infrastructure because the cells are the featured ingredient in our research. We have a deepening panel of immortal human and rodent cell lines for pilot testing to a license. We offer flexible cell engineering services agreements with a deep expertise in cell immortalization. Contact us with a query, 205-307-6535, Ext 1 or 3, and we will follow up to discuss your needs.

 'Human Body in a Microtiter Plate' Safety versus Toxicity Assessment of Lead Compounds.

This is a new 'gold standard' in in vitro cellular toxicity analysis. Our basic package is the assessment of 5 doses of a lead compound versus vehicle in quadruplicate across human skin, lung, liver and kidney cells. This has become popular, as an aid to determine triage versus movement forward on select lead compounds into pre-clinical animal testing or in 'peace of mind' analysis of a key ingredient and its safety when exposed to human cells of interest. Inquire! 205.307.6535 Ext. 1 or 3 and/or erik@discoverybiomed.com